Pharmacogenetics-pivotal to the future of the biopharmaceutical industry

Drug Discovery Today

Volumn 15, Issue 9-10, 2010, Pages 325-327

  Foot, Elizabeth ^a   Kleyn, Dominique ^a   Palmer Foster, Emma ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CETUXIMAB; CLOPIDOGREL; HLA B57 ANTIGEN; TRASTUZUMAB; WARFARIN;

CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; EDITORIAL; GENETIC SCREENING; GENETIC VARIABILITY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; PATIENT SELECTION; PHARMACOGENETICS; SKIN ALLERGY;

BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; PHARMACOGENETICS;

EID: 77952551569     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.03.004     Document Type: Editorial

References (5)

1. Challenge and opportunity on the critical path of new medical products. FDA White Paper 2004.
2. Pirmohamed M., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004, 329:15-19.
3. Hughes D.A., et al. Cost-effectiveness analysis of HLA B 5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14:335-342.
4. The stratification of disease for personalised medicines. ABPI White Paper April 2009.
5. Genomic Medicine. House of Lords, Science and Technology Committee Report July 2009.